GlassScriptPhysician profile
William Clark Koonce
NPI 1124010095
$7,678.79
in general payments reported to CMS, 2019-2025
34 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $1,137 · 2021: $1,323 · 2022: $1,392 · 2023: $1,204 · 2024: $1,055 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.51 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,008.00 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $841.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $552.31 | 2019-2025 | Farxiga, Airsupra |
| Gilead Sciences, INC. | $495.42 | 2019-2022 | |
| Tanabe Pharma America, INC. | $415.14 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $392.51 | 2019-2023 | Xarelto |
| Abbvie INC. | $346.29 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.23 | 2019-2025 | Jardiance, Synjardy |
| Viiv Healthcare Company | $258.75 | 2019-2025 | Dovato, Cabenuva |
| Amarin Pharma, INC. | $238.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $220.96 | 2022-2024 | |
| Eisai INC. | $175.98 | 2020-2025 | |
| Lilly USA, LLC | $126.13 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Harmony Biosciences LLC | $124.56 | 2025 | |
| Exact Sciences Corporation | $109.06 | 2023-2024 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $107.16 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $97.45 | 2019-2024 | Verquvo, Steglatro, Januvia |
| Glaxosmithkline, LLC. | $96.16 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $93.01 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $88.64 | 2020-2023 | Ozempic, Rybelsus |
| Idorsia Pharmaceuticals US INC | $84.06 | 2022-2023 | Quviviq |
| Allergan, INC. | $82.13 | 2020 | |
| Astellas Pharma US INC | $70.99 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $56.55 | 2022-2024 | Onpattro |
| Almatica Pharma LLC | $51.69 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $49.60 | 2020-2021 | |
| Insmed, INC. | $47.52 | 2025 | Arikayce |
| Boston Scientific Corporation | $41.72 | 2022 | |
| Smith+Nephew, INC. | $31.19 | 2024 | Grafix Pl |
| Janssen Biotech, INC. | $18.08 | 2025 | Tremfya |
| Therapeuticsmd, INC. | $17.29 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.45 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.72 | 2021 | |
| Vertiflex, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Koonce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.